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The synthesis and characterisation of a new class of DTPA
bis(amide) linked glycoconjugates of different sugars [lactose
(Lac) and galactose (Gal)] and valencies (di and tetra) and
their LnIII complexes is reported. The 1H NMR spectra of the
SmIII and EuIII complexes of DTPAGal2, DTPAGal4, and
DTPALac2, obtained between 7 and 80 °C, indicate that se-
veral of the four possible diastereoisomeric pairs of structures
resulting from the chirality of the three bound DTPA nitrogen
atoms are present in solution, with different relative popula-
tions. The dynamic effects of racemisation of the central ni-
trogen atom in the NMR spectra show that this process is fast
at 60 °C for the SmIII complexes and slow at 7 °C for the EuIII
complexes. The in vitro r1 nuclear magnetic relaxation dis-
Introduction
Magnetic resonance imaging (MRI) is one of the fastest
growing techniques in medical diagnosis due to the excel-
lent spatial resolution and contrast, in particular for soft
tissues. The image contrast is based mainly on the differ-
ences of water proton longitudinal (1/T1) and transversal
(1/T2) relaxation rates in different tissues. This contrast can
be enhanced with the administration, prior to the scan, of
paramagnetic contrast agents (CAs), usually GdIII (4f7)
complexes,[1,2] which accelerate the proton relaxation pro-
cesses in the surrounding water through dipolar interactions
between the unpaired electron spin of the metal ion and the
proton nuclei of the water molecules. The GdIII chelate of
DTPA [DTPA = 3,6,9-tris(carboxymethyl)-3,6,9-triazaun-
decane-1,11-dioic acid)], [Gd(DTPA)(H2O)]2–, was the first
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persion (NMRD) of the water protons of the GdIII–DTPA bis-
(amide) glycoconjugate containing two lactosyl moieties
[GdIII–DTPALac2] was studied, yielding the molecular
parameters that govern its relaxivity. Its r1 value, at 25 °C and
20 MHz, is 13% higher than that reported for GdIII chelates
of lower molecular weight DTPA bis(amides), such as DTPA-
BMA, consistent with a five times larger τR value. The water
exchange rate, kex, and the electron spin relaxation parame-
ters of the GdIII–DTPALac2 complex are within the usual
range for similar GdIII–DTPA bis(amide) chelates.
(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2005)
contrast agent (CA) used for human MRI, under the name
of Magnevist®.[3] Its success stimulated further studies on
modifications of its structure, leading, amongst others, to
the neutral derivative [Gd(DTPA-BMA)(H2O)] [Omni-
scan®; DTPA-BMA = diethylenetriaminepentaacetic acid
N,N-bis(methylamide)], in which two carboxylate groups
have been converted into amide functions.[4] These, as well
as other hydrophilic linear or macrocyclic GdIII chelates of
similar dimensions and simplicity, once injected, rapidly dif-
fuse from the intravascular space into the interstitial space,
but do not enter the intracellular space. Their rapid renal
elimination produces a rapid decrease in tissue Gd concen-
tration.[5]
Although much used, for example in neuropathological
conditions, which are often associated with disruption of
the blood brain barrier (BBB) or altered capillary perme-
ability, these extracellular fluid (ECF) CAs also have in-
herent disadvantages due to their lack of biospecificity, low
relaxivities, and poor uptake elsewhere in the body. Their
rapid diffusion from the vasculature limits their uses as
blood pool agents, for example in estimates of blood flow
and perfusion. For such applications, several formulations
of DTPA conjugates have been tested, both through coval-
ent binding of the GdIII chelate to suitable macromolecules
(albumin,[6] dextran,[7] polylysine,[8] dendrimers[9]) or non-
covalent binding to HSA (human serum albumin),[10] for
example the Gd–DTPA derivative MS-325.[11] The search
for new ligands with high tissue and/or organ specificity
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started with hepatobiliary CAs, such as GdIII chelates,
which are hepatocyte-specific and are excreted through the
hepatobiliary system. Amongst these are GdIII chelates of
DTPA-derived ligands bearing various lipophilic substitu-
ent groups which promote specific carrier-mediated uptake
into the hepatocytes, such as benzyloxymethyl in [Gd-
(BOPTA)(H2O)]2– [BOPTA = 4-carboxy-5,8,11-tris-
(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-
oic acid][12] and ethoxybenzyl in [Gd(EOB-DPTA)(H2O)]2–
[EOB-DTPA = (S)-N-{2-[bis(carboxymethyl)amino]-3-(4-
ethoxyphenyl)propyl}-N-{2-[bis(carboxymethyl)amino]-
ethyl}glycine].[13] Liposomes can also be efficient carriers to
deliver GdIII-based CAs to the liver and spleen and hence
enhance their MRI image contrast. The amphiphilic
Gd(DTPA)–stearylamide, for example, is incorporated into
the phospholipid lamella of egg lecithin and cholesterol
liposomes.[14]
Figure 1. Structures of the DPTA bis(amide) glycoconjugates (the labelling of the protons for spectral assignments is shown).
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The hepatocyte cells on liver express a tissue-specific lec-
tin (hepatic lectin) that recognizes terminal β-galactosyl res-
idues on desialylated glycoproteins − the asialoglycoprotein
receptor (ASGPR).[15] Liver targeting has been successfully
achieved through conjugation of pharmaceutical agents to
galactose/lactose.[16] Moreover, a multivalence effect has
been demonstrated on the liver uptake of glycoconjugates
(tetra  tri  di  mono).[17] Several agents that rely on
macromolecular bioconjugates and on polymer scaffolds
have been described for hepatic imaging through the tar-
geting of the ASGPR.[18–25] These agents have the drawback
of being inherently polydisperse and ill characterised.
In a previous paper we reported the synthesis and
physicochemical characterisation of a new class of multi-
valent glycoconjugates − LnIII chelates of the tetraazatetra-
carboxylate chelator DOTA conjugated to glycodendri-
meric moieties [DOTA = 1,4,7,10-tetrakis(carboxymethyl)-
J. P. André, J. A. Martins et al.FULL PAPER
1,4,7,10-tetraazacyclododecane].[26] Previous to our work,
only a class of low molecular weight and well-characterised
galacto/mannopyranosyl conjugates of DOTA-like chela-
tors had been described for potential MRI and scinti-
graphic applications.[27] These monovalent GdIII–glycocon-
jugates are responsive contrast agents activated by galactos-
idase/mannosidase-mediated hydrolysis.[28] In this paper we
report the synthesis and characterisation of (thio)glycocon-
jugates of the linear chelator DTPA, namely the DTPA bis-
(amides) 1 and 2 with different terminal sugar residues −
galactose (Gal) and lactose (Lac) − and different valences
(2 and 4; Figure 1). The thioglycosides are galactosidase-
resistant ligands that probe a conformational space and dis-
play biological activities very similar to that of their O-
linked natural counterparts, thus ensuring an increased
metabolic stability in vivo.[29] The physicochemical charac-
terisation of some of their LnIII complexes in aqueous solu-
tion by 1H NMR and water 1H NMRD studies is also de-
scribed. The proton relaxivity of the GdIII chelates de-
scribes the efficiency of the magnetic dipolar coupling be-
tween the water proton nuclei and the paramagnetic metal
ion, therefore it is a direct measure of the efficacy of the
chelate as a CA.
Results and Discussion
Synthesis of the Ligands
The synthesis of the DTPA bis(amides) 1 and 2 (Fig-
ure 1) was undertaken through a well-established route con-
sisting of the derivatisation of the commercially available
DTPA bis(anhydride) with amine-functionalised blocks.
Two different types of amine-functionalised sugar blocks
were prepared: a monovalent block 5 (Scheme 1) and a di-
valent glycodendrimer block 9 (Scheme 2).[26,31] The stan-
dard DCC/HOBT coupling procedure was found to be suc-
cessful for preparing the fully protected amino-function-
alised sugar blocks. These compounds were deprotected
Scheme 2. a) TFA/DCM (1:3); b) i. DIPEA/DCM; ii. DCC/HBT, DCM.
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with TFA/CH2Cl2 to afford the terminal amines 6 and 10
as their TFA salts.
Scheme 1. a) DCC/HBT, DCM; b) TFA/DCM (1:3).
In order to ensure the formation of the required bis-
(amides), the amino-functionalised blocks 6 and 10 were
used in a slight excess, over two mol-equiv. in relation to the
DTPA bis(anhydride) block (Scheme 3). The intermediate
sugar-protected bis(amides) were carried through and de-
protected with KOH in methanol/water to give the final
compounds 1 and 2 in reasonable yields.
NMR Studies of the LnIII Glycoconjugates
The 1H NMR spectra of the 1:1 diamagnetic (LaIII) and
paramagnetic (SmIII and EuIII) complexes with the ligands
DTPAGal2, DTPALac2 and DTPAGal4 were obtained in
D2O at pH = 7.5 as a function of temperature (7, 25, 40,
60 and 80 °C; see Figures 2–4 for some typical spectra). The
spectra of the LaIII complexes show many identical reso-
nances to those of the corresponding free ligand at the same
pH for the protons of the sugar rings and bridging arms
(Figure 2). However, the protons of the DTPA moiety, or
next to it, such as CH2(f), give more complex resonances as
a result of ion coordination: a multiplet at δ = 2.92 ppm for
CH2(f), multiplets at δ = 2.95, 2.78, 2.68 and 2.45 ppm for
the backbone NCH2CH2N protons, and a series of partially
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Scheme 3. a) i. DIPEA/DCM; ii. DMF/Py; b) i. KOH/EtOH; ii. Amberlyst 15, elution with NH3.
Figure 2. 1H NMR spectrum of LaIII–DTPAGal2 glycoconjugate in D2O, pH = 7.0, T = 25 °C.
overlapping AB patterns in the δ = 3.2–3.5 ppm region for
the CH2 protons of the acetate and amide arms, quite sim-
ilar to what has been described for [La(DTPA)]2– and other
La[DTPA bis(amides)].[32–36] For the SmIII and EuIII com-
plexes, the ligand protons far from the paramagnetic centre,
at the sugar rings (H-1–H-6) and at bridging arms [CH2(g–
m)], show very small paramagnetic broadenings and their
shifts are easily assigned (see Figure 3).[36] The strongly
shifted and broadened proton resonances of the side chain
CH2(f) and the CH2 of the DTPA amide moiety could not
be specifically assigned, despite showing some features sim-
ilar to the corresponding paramagnetic complexes of the
parent DTPA and some DTPA bis(amide) ligands.[36–42]
For the SmIII complexes, most of these strongly shifted
resonances are too broad to be detected at 25 °C but
sharpen at higher temperatures. At 60 °C some appear in
the diamagnetic region (δ = 5.8–4.8 and 3.3–0.6 ppm) and
seven are shifted to the low frequency δ = 0.1 to –1.4 ppm
region (Figure 3). In contrast, in the EuIII complexes the
shifted resonances are quite sharp at low temperature (7 °C,
see Figure 4): ten resonances are observed in the high-fre-
quency δ = 35–15 ppm region, about eight in the δ = 10–
5 ppm region and about twenty in the δ = –3 to –18 ppm
region. These are totally broadened when the temperature
is increased to 25 °C, but at 60 °C some sharp, less shifted
resonances reappear, for example in the δ = 6.2 to
–10.2 ppm region (data not shown).
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In LnIII complexes of DTPA bis(amides) with non-chiral
centres in the side chains, with a cation nine-coordinate by
one inner-sphere water molecule and eight ligand donor
atoms, all three bound nitrogen atoms are chiral and four
diastereoisomeric pairs of enantiomers are possible, leading
to a maximum of eight NMR signals for each group of
magnetically equivalent protons.[36,40] This type of complex
can undergo two distinct isomerisation processes in solu-
tion. The racemisation of the terminal N atoms, involving
decoordination-inversion-coordination of the N atoms and
the neighbouring acetate groups, has a high energy barrier.
A lower energy process involves racemisation of the central
nitrogen atom by interconversion between the two possible
conformations of the ethylene bridges, which results in the
magnetic averaging of the two halves of the complex around
the central glycinate group of DTPA and reduces by half
the number of observed resonances.[36,40] This is the dy-
namic process observed in the present study, which is fast
at 60 °C for the SmIII complexes and slow at 7 °C for the
EuIII complexes due to the much larger dipolar shifts in-
duced by EuIII relative to SmIII.
The total number of strongly shifted proton resonances
observed for the SmIII and EuIII complexes studied here,
although they could not be assigned, leads to the unambig-
uous conclusion that they occur as more than one isomer
in solution. A comparison of the 1H NMR spectra with
those of corresponding DTPA complexes[33,39] suggests that
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Figure 3. 1H NMR spectrum of SmIII–DTPAGal2 glycoconjugate in D2O, pH = 7.0, T = 60 °C.
Figure 4. 1H NMR spectrum of EuIII–DTPAGal2 glycoconjugate in D2O, pH = 7.0, T = 7 °C.
the strongly shifted resonances at low frequencies for the
SmIII complex and at high frequencies for the EuIII complex
correspond to two CH2 protons of the DTPA ethylenedi-
amine backbone, which, in the DTPA complexes, have the
largest induced dipolar shifts.[36,39] With this assumption,
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the minimum of seven low-frequency-shifted resonances
observed for the SmIII complex at high temperature (Fig-
ure 3), resulting from two ethylenic protons, confirms that
several of the four possible isomers are present in solution.
This is also in agreement with the observation of a mini-
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mum of ten high-frequency-shifted resonances in the EuIII
complex at high temperature (out of a maximum of sixteen)
for these two ethylenic protons (Figure 4). The LnIII com-
plexes of other DTPA bis(amides), such as DTPA-BPA
[BPA = bis(propylamide)] and DTPA-BENGALAA
{BENGALAA = N,N-bis[N-(aza-d-galacto-5,6,7,8,9-
pentahydroxynonyl)carbamoylmethyl]amide},[35,41] show
the presence of four diastereoisomeric pairs, while for bis-
(amides) containing long (C14 to C18) aliphatic chains only
two pairs have been detected in solution.[42]
Water Proton Relaxation (NMRD) Studies of GdIII-
DTPALac2
The efficiency of a contrast agent is given by its proton
relaxivity, defined as the paramagnetic enhancement of the
longitudinal water proton relaxation rate at a concentration
of 1 mm (r1, in s–1 mm–1). Proton relaxivity has contri-
butions from interactions of the GdIII ion with the inner-
sphere water protons (inner-sphere relaxivity) as well as
with the bulk water protons (outer-sphere relaxivity). The
inner-sphere term is determined by the exchange rate of the
inner-sphere water protons (usually equal to the water ex-
change rate, kex), the rotational correlation time of the com-
plex (τR) and the longitudinal and transverse electronic re-
laxation rates of the GdIII (1/T1e and 1/T2e). The outer-
sphere contribution to the overall proton relaxivity depends
on the electron spin relaxation rates and the diffusion coef-
ficient for the diffusion of a water proton away from a GdIII
chelate (see Supporting Information).[43]
The water proton longitudinal relaxivity of the GdIII–
DTPALac2 chelate was measured in aqueous solution at 25
and 60 °C at proton Larmor frequencies between 0.2 and
20 MHz. The NMRD profiles obtained (Figure 5) are typi-
cal of low molecular weight GdIII chelates. They were fitted
to the usual Solomon–Bloembergen–Morgan relationship
that relates the paramagnetic relaxation rates to the micro-
scopic parameters of the GdIII chelates (see equations in
Supporting Information). In the analysis of the NMRD
profiles we fixed the number of inner-sphere water mole-
cules to one, and the water exchange rate and its activation
enthalpy to values that were previously determined for sim-
ilar DTPA bis(amide) complexes (kex298 = 0.40×106 s–1 and
ΔH‡ = 40.0 kJmol–1).[43] The diffusion coefficient and its
activation energy were also fixed to common values
(DGdH298 = 24×10–10 m2 s–1; EDGdH = 20 kJmol–1), as these
Table 1. Parameters obtained from the analysis of the NMRD profiles for GdIII–DTPALac2 in comparison with other GdIII complexes.
DTPA[44] DTPA-BMA[44] DTPA-BENGALAA[41] DTPALac2 DOTALac2[26]
[bis(amide)] [bis(amide)] [bis(amide)] [mono(amide)]
kex298 [106 s–1] 3.3 0.45 0.22 0.40[a] 1.2[a]
ΔH‡ [kJmol–1] 51.6 47.6 42.5 40.0[a] 30.0[a]
τrH298 [ps] 58 66 265 332±10 306
ERH [kJmol–1] 17.3 21.9 19.7 36.3±0.2 29.9
τv298 [ps] 25 25 16 10±2 33
Ev [kJmol–1] 1.6 3.9 5.5 1[a] 1[a]
Δ2 [1020 s–2] 0.46 0.41 0.53 0.63±0.02 0.12
[a] Parameters in italics have been fixed in the fit.
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two parameters are not particularly dependent on the na-
ture of low molecular weight complexes.[43,44] Thus, in the
analysis of the proton relaxivities we fitted the rotational
correlation time, τR, its activation energy, ER, and the
parameters describing the electron spin relaxation, i.e. the
trace of the square of the transient zero-field-splitting
(ZFS) tensor, Δ2, and the correlation time for the modula-
tion of the ZFS, τv.[45] The parameters obtained for the
GdIII–DTPALac2 conjugate are presented in Table 1 and
compared with those available for other relevant small GdIII
complexes. The fits of the NMRD profiles obtained are
shown in Figure 5.
Figure 5. Variable-temperature NMRD profiles for GdIII–DTPA-
Lac2; T = 25 °C (triangles); and 60 °C (circles). The lines represent
the least-squares fit to the experimental data points as described in
the text.
The relaxivity of GdIII–DTPALac2 (mol. wt. = 1569) at
25 °C and 20 MHz is 5.72 mm–1 s–1, which corresponds to
an increase of 13% compared to that for the commercial
contrast agent GdIII–DTPA-BMA, which is a lower mol-
ecular weight DTPA bis(amide) complex (mol. wt. =
574).[44] This relaxivity difference is consistent with the five-
fold increase in the rotational correlation time, as it is τR
that dominates the high-field NMRD values. Another
DTPA bis(amide) chelate, GdIII–DTPA-BENGALAA, with
an intermediate molecular weight (963), also has an inter-
mediate τR value.[41] The temperature dependence of the
NMRD profiles clearly shows that the proton relaxivity of
these small molecular weight chelates is limited by fast rota-
tion: proton relaxivities increase when the temperature de-
creases; thus, the rotation slows down. The parameters ob-
tained for the electron spin relaxation of the GdIII complex
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are also within the usual range for similar GdIII–DTPA bi-
s(amide) chelates. Although the simplified model of elec-
tron spin relaxation used here is not fully adequate to de-
scribe GdIII chelates,[46] the application of the novel theories
requires EPR data in a large field range, which is beyond
the scope of the present study.
Conclusions
We have devised the synthesis of a new class of hydro-
philic glycoconjugate DTPA bisamides. Their dendrimeric
architecture is especially suited for the variation of the val-
ence of the glycoconjugates from a reduced number of
building blocks in an interactive fashion. The 1H NMR
studies of the SmIII and EuIII chelates of these glycoconju-
gates in aqueous solution, despite being too complex to be
fully assigned, unambiguously show that these complexes
occur as more than one of the isomers that result from the
chirality of the three bound ligand nitrogen atoms. This is
to be compared with the presence of the four possible dia-
stereoisomeric pairs of enantiomers for the LnIII complexes
of other DTPA bis(amides) with smaller substituents, such
as DTPA-BMA and DTPA-BENGALAA,[35,41] while for
bis(amides) containing long, micelle-forming, aliphatic
chains, only two pairs have been detected in solution,[42]
possibly stabilized by intermolecular interactions.
The NMRD studies of the GdIII–DTPALac2 glycocon-
jugate chelate are compatible with the presence of one in-
ner-sphere water molecule. The value found for its r1 re-
laxivity at 25 °C and 20 MHz is 13% higher than that re-
ported for GdIII chelates of lower molecular weight DTPA
bis(amides), such as DTPA-BMA, consistent with a larger
τR value. The τR value of these GdIII chelates is expected to
increase linearly with molecular weight, as long as the in-
ternal mobility of the side chains does not change signifi-
cantly, thereby leading to a proportional increase of the
20 MHz relaxivity. This result suggests that the relaxivity of
the tetravalent GdIII–DTPAGal4 glycoconjugate (mol. wt.
= 2088) would be substantially higher. Their potential to
target the ASGPR (studies under way), makes these com-
pounds potentially useful for medical imaging agents using
gamma scintigraphy, while they also constitute a promising
first step towards the design of ASGPR-targeted MRI con-
trast agents, which will depend on the optimisation of their
relaxivity.
Experimental Section
Materials and Equipment: Chemicals were purchased from Sigma–
Aldrich and used without further purification. Solvents used were
of reagent grade and were purified by usual methods. Reactions
were monitored by TLC on Kieselgel 60 F254 (Merck) on alumin-
ium support. Detection was by examination under UV light
(254 nm), by adsorption of iodine vapour or by charring with 10%
sulfuric acid in ethanol. Flash chromatography was performed on
Kieselgel 60 (Merck, mesh 230–400). The relevant fractions from
flash chromatography were pooled and concentrated under reduced
pressure, at a temperature below 40 °C. FAB mass spectra (positive
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mode) were recorded with a VG Autospec mass spectrometer with
3-nitrobenzyl alcohol (NBA) as matrix. Electrospray ionisation
(ESI) mass spectra were obtained for compounds with molecular
weights above 2000. 1H (1D and 2D) and 13C NMR spectra were
recorded with a Varian Unity Plus 300 NMR spectrometer op-
erating at 299.938 MHz and 75.428 MHz, for 1H and 13C, respec-
tively. Chemical shifts (δ) are given in ppm relative to the CDCl3
solvent (1H: δ = 7.27 ppm; 13C: δ = 77.36 ppm) as internal stan-
dard. For 1H and 13C NMR spectra recorded in D2O, chemical
shifts (δ) are given in ppm relative to TSP as internal reference (1H:
δ = 0.0 ppm) and tert-butyl alcohol as external reference (13C: CH3
δ = 30.29 ppm). 13C NMR spectra were proton broad-band decou-
pled using a GARP-1 modulated decoupling scheme. Assignments
of the 1H and 13C NMR spectra were aided by recording two-
dimensional DQF-COSY and HMQC spectra. The pD of the D2O
solutions was adjusted with DCl or CO2-free NaOD and converted
to pH values using the isotopic correction pH = pD – 0.4. The pD
values were measured with a HANNA pH-meter with a HI1310
combined electrode (HANNA instruments, Italy). The 1/T1 nuclear
magnetic relaxation dispersion (NMRD) profiles of the water pro-
tons at 25 and 60 °C were obtained with a Spinmaster FFC fast
cycling NMR relaxometer (Stelar), covering a continuum of mag-
netic fields from 5×10–4 to 0.47 T (corresponding to a proton
Larmor frequency range of 0.022–20 MHz). The GdIII concentra-
tion was verified by ICP measurement (Perkin–Elmer Instruments,
Optim 2000 DV).
Synthesis of Fully Protected Hexanediamine-Functionalised Mono-
valent Thioglycosides 5a and 5b. Typical Procedure for 5a: A solu-
tion of peracetylated (galactosylthio)propionic acid (3a;[29a]
0.375 g, 0.859 mmol), 1,6-hexanediamine monoBoc (4; 0.169 g,
0.781 mmol) and HBT (1-hydroxybenzotriazol; 0.140 g,
0.940 mmol) in dichloromethane (10 mL) was ice-cooled. A solu-
tion of DCC (dicyclohexylcarbodiimide; 0.194 g, 9.40 mmol) in
dichloromethane (5 mL) was added dropwise to this solution. After
15 min, the reaction mixture was removed from the ice bath and
allowed to reach room temperature. The reaction mixture was fur-
ther stirred at room temperature overnight. The DCU (dicyclohex-
ylurea) precipitate was removed by filtration and washed with
dichloromethane. The filtrate was concentrated under reduced pres-
sure to give a viscous syrup. This material was taken up in ethyl
acetate (100 mL) and sequentially washed with KHSO4 (aq. 1 m;
3×50 mL), NaHCO3 (satd. sol.; 3×50 mL) and brine (50 mL). The
organic phase was concentrated under reduced pressure to give a
white foam. Purification by flash chromatography (CH2Cl2/MeOH;
100% CH2Cl2  50% MeOH) afforded the title compound as a
white foam (0.480 g, 97% yield). 1H NMR (300 MHz, CDCl3): δ
= 1.34 (m, 4 H, NHCH2CH2CH2), 1.43 (s, 9 H, tBu), 1.50 (m, 4
H, NHCH2CH2), 1.99, 2.05, 2.06 and 2.16 (s, 12 H, 4×OAc), 2.50
(m, 2 H, SCH2CH2), 2.88–3.06 (m, 2 H, SCH2), 3.09 [m, 2 H,
CH2NHC(O)OtBu], 3.24 [m, 2 H, C(O)NHCH2], 3.48 (br. m, 1 H),
3.95 (ddd, J = 7.2, 5.7 and 0.9 Hz, 1 H, H-5), 4.11 (dd, J = 11.2
and 5.7 Hz, 1 H, H-6a), 4.19 (dd, J = 11.2 and 7.2 Hz, 1 H, H-6b),
4.54 (d, J = 9.9 Hz, 1 H, H-1), 5.04 (dd, J = 10.2 and 3.3 Hz, 1 H,
H-3), 5.23 (app t, J = 9.9 Hz, 1 H, H-2), 5.43 (dd, J = 3.3 and
0.9 Hz, 1 H, H-4), 5.98 (br. t, 1 H, NH) ppm. HRMS (FAB+,
NBA): calcd. for C28H47N2O12S [M + H]+ 635.2844; found
635.2856. 5b: Starting from peracetylated (lactosylthio)propionic
acid (3b;[29a] 1.70 g, 2.35 mmol) and 1,6-hexanediamine monoBoc
(4; 0.507 g, 2.35 mmol), the title compound 5b was obtained as a
white foam (2.01 g, 93%). 1H NMR (300 MHz, CDCl3): δ = 1.33
(m, 4 H, NHCH2CH2CH2), 1.42 (s, 9 H, tBu), 1.70 (m, 4 H,
NHCH2CH2), 1.97, 2.04, 2.05, 2.07, 2.13 and 2.16 (s, 21 H,
7× OAc), 2.46 (t, J = 6.6 Hz, 2 H, SCH2CH2), 2.81 (m, 1 H,
Lanthanide(iii) Chelates of DTPA Bis(amide) Glycoconjugates FULL PAPER
SCHaHb), 3.03 (m, 1 H, SCHaHb), 3.08 [m, 2 H, CH2NHC(O)-
OtBu], 3.21 (m, 2 H, NHCH2), 3.45 (m, 1 H) 3.59 (m, 1 H, H-5),
3.78 (app t J = 9.6 Hz, 1 H, H-4), 3.89 (app t, J = 7.0 Hz, 1 H, H-
5), 4.03–4.16 (m, 3 H), 4.28 (m, 1 H), 4.52 (d, J = 7.8 Hz, 1 H, H-
1), 4.65 (d, J = 10.5 Hz, 1 H, H-1), 4.90 (app t, J = 9.6 Hz, 1 H,
H-2), 4.96 (dd, J = 10.2 and 3.3 Hz, 1 H, H-3), 5.09 (dd, J = 10.5
and 7.8 Hz, 1 H, H-2), 5.19 (app t, J = 9.3 Hz, 1 H, H-3), 5.34 (d,
J = 2.4 Hz, 1 H, H-4), 6.30 (br. t, 2 H, NHCO) ppm. MS (FAB+,
NBA): m/z (%) = 923 (3) [M + H]+. HRMS (FAB+, NBA): calcd.
for C40H63N2O20S [M + H]+ 923.3695; found 923.3683.
Synthesis of Fully Protected Amino-Functionalised Divalent 9: A
solution of divalent thiogalactoside 7[26] (0.968 g, 0.895 mmol) was
stirred overnight in CH2Cl2/TFA (3:1, 10 mL). The solvent was re-
moved under reduced pressure to give a light yellow foam, which
was redissolved in dichloromethane (DCM; 10 mL). The solvent
was then removed under reduced pressure. This procedure was re-
peated several times and the material was further dried under vac-
uum to give the carboxylic acid deprotected compound 8 as a vis-
cous, light-yellow foam. 1H NMR analysis revealed the disappear-
ance of the signal at δ = 1.4 ppm assigned to the tert-butyl group.
No further purification or characterisation was carried on this ma-
terial. All the material obtained (we assumed a 100% yield for the
deprotection reaction) was dissolved in ice-cooled DCM (10 mL)
and titrated (pH paper) to pH = 9–10 with DIPEA (diisopropyle-
thylamine). To this solution was added a solution of 1,6-hexanedia-
mine monoBoc (4; 0.230 g, 1.07 mmol) in dichloromethane (5 mL)
and HBT (0.140 g, 0.940 mmol). A solution of DCC (0.230 g,
1.10 mmol) in dichloromethane (5 mL) was then added dropwise.
After 15 min, the reaction mixture was removed from the ice bath
and allowed to reach room temperature. The reaction mixture was
further stirred at room temperature overnight. The DCU precipi-
tate was removed by filtration and washed with dichloromethane.
The filtrate was concentrated under reduced pressure to give a vis-
cous syrup. This material was taken up in ethyl acetate (150 mL)
and sequentially washed with NaHCO3 (satd. sol.; 3×100 mL) and
brine (100 mL). The organic phase was concentrated under reduced
pressure to give a light-yellow foam. Purification by flash
chromatography (CH2Cl2/MeOH; 100% CH2Cl2  50% MeOH)
afforded the title compound as a white foam (1.01 g, 92% yield).
1H NMR (300 MHz, CDCl3): δ = 1.32 [m, 4 H, C(O)
NHCH2CH2CH2], 1.43 (s, 9 H, tBu), 1.51 [m, 4 H, C(O)
NHCH2CH2], 1.72 (m, 4 H, NCH2CH2), 1.99, 2.05, 2.06 and 2.16
(s, 24 H, 8×OAc), 2.52 (m, 8 H, overlapping signals from
SCH2CH2 and NCH2), 2.88–3.14 [m, 8 H, overlapping signals from
SCH2, NCH2C(O) (singlet at 3.02) and CH2NHC(O)OtBu], 3.29
[m, 6 H, NCH2CH2CH2 and NCH2C(O)NHCH2], 3.40–3.56 (m, 1
H), 3.96 (td, J = 6.4 and 0.9 Hz, 2 H, H-5), 4.09 (dd, J = 11.4 and
6.3 Hz, 2 H, H-6a), 4.20 (dd, J = 11.2 and 6.4 Hz, 2 H, H-6b), 4.56
(d, J = 10.2 Hz, 2 H, H-1), 4.74 (br. t, 1 H, NH), 5.05 (dd, J =
10.0 and 3.3 Hz, 2 H, H-3), 5.25 (app t, J = 9.9 Hz, 2 H, H-2), 5.44
(dd, J = 3.3 and 0.9 Hz, 2 H, H-4), 6.74 (br. t, 2 H, NH), 7.10 (br.
t, 2 H) ppm. MS (FAB+, NBA): m/z (%) = 1223 (100) [M – H]+.
HRMS (FAB+, NBA): calcd. for C53H86N5O23S2 [M + H]+
1224.5155; found 1224.5119.
Synthesis of DTPA Glycoconjugate Bis(amides9 1 and 2. Typical
Procedure Illustrated for DTPAGal2 (1a): A solution of fully pro-
tected amino-functionalised monovalent thiogalactoside 5a
(0.618 g, 0.973 mmol) was stirred overnight in CH2Cl2/TFA (3:1,
10 mL). The solvent was removed under reduced pressure to give
a light-yellow foam, which was redissolved in DCM (10 mL); the
solvent was then removed under reduced pressure. This procedure
was repeated several times and the material was further dried under
vacuum to give a viscous, light-yellow foam of 6a. 1H NMR analy-
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sis revealed the disappearance of the signal at δ = 1.47 ppm as-
signed to the tert-butyl group. No further purification or character-
isation was carried out on this material. All the material obtained
(we assumed a 100% yield for the deprotection reaction) was dis-
solved in ice-cooled DCM (5 mL) and titrated (pH paper) to pH
= 9–10 with DIPEA. This solution was added to a solution of
DTPA bis(anhydride) (0.158 g, 0.442 mmol) in DMF (40 mL) and
pyridine (1 mL). The reaction mixture was stirred at room tempera-
ture overnight and concentrated under reduced pressure to give a
colourless oil. This material was carried through without further
purification or characterisation. The residue was redissolved in a
mixture of ethanol (10 mL) and KOH (aq. sol. 1 m, 10 mL) and
stirred at room temperature overnight. The reaction mixture was
adjusted to pH  1 with Amberlyst 15. The resin was transferred
into a column, thoroughly washed with water and eluted with aq.
0.5 m NH3. The relevant fractions were pooled and concentrated
under reduced pressure (temperature  40 °C) to give the fully de-
protected glycoconjugate as an off-white solid (0.342 g, 71% yield
over two steps). 1H NMR (300 MHz, D2O, pH = 7.0): δ = 4.48 (d,
J = 9.0 Hz, 2 H, H-1), 3.54 (app t, J = 9.0 Hz, 2 H, H-2), 3.64 (dd,
J = 9.0 and 3.3 Hz, 2 H, H-3), 3.70 (m, 2 H, H-4), 3.96 (app d, J
= 3.3 Hz, 2 H, H-5), 3.73 (m, 4 H, H-6a + H-6b), 1.32 [m, 8 H,
C(O)NHCH2CH2CH2], 1.51 [m, 8 H, C(O)NHCH2CH2], 3.20 [m,
8 H, C(O)NHCH2], 2.60 (m, 4 H, SCH2CH2), 2.95–3.01 (m, 4 H,
SCH2), 3.24 [s, 4 H, DTPA amide NCH2C(O)], 3.76 (s, 2 H, DTPA
central acetate NCH2CO2–), 3.40 (s, 4 H, DTPA terminal acetate
NCH2CO2–), 3.34, 3.08 (two m, 8 H, DTPA skeleton NCH2) ppm.
13C NMR (75.6 MHz, D2O): δ = 86.18 (C-1), 69.67 (C-2), 74.05
(C-3), 79.07 (C-4), 68.94 (C-5), 61.30 (C-6), 25.90, 25.83 [C(O)
NHCH2CH2CH2], 28.29, 28.42 [C(O)NHCH2CH2], 39.23, 39.54
[C(O)NHCH2], 26.49 (SCH2), 36.57 (SCH2CH2), 58.86 [DTPA
amide NCH2C(O)], 54.58 (DTPA central acetate NCH2CO2–),
58.95 (DTPA terminal acetate NCH2CO2–), 50.59, 52.79 (DTPA
skeleton NCH2), 170.77, 173.02, 174.28, 178.40 [DTPA acetate
NCH2CO2– and amide NCH2C(O), other CH2C(O)NH] ppm. MS
(FAB+, NBA): m/z (%) = 1091 (23) [M + H+]. HRMS (FAB+,
NBA) calcd. for C44H80N7O20S2 [M + H]+: 1090.4899; found
1090.4859.
DTPALac2 (1b): Fully protected monovalent thiolactoside 5b
(0.997 g, 1.08 mmol) was deprotected as described for compound
1a. Reaction with DTPA bis(anhydride) (0.183 g, 0.512 mmol), fol-
lowed by deprotection and purification afforded glycoconjugate 1b
as an off-white solid (0.345 g, 48% yield over two steps). 1H NMR
(300 MHz, D2O, pH = 7.0): δ = 4.46 (d, J = 7.8 Hz, 2 H, H-1),
3.54 (dd, J = 10.2 and 7.8 Hz, 2 H, H-2), 3.63 (dd, J = 10.2 and
3.3 Hz, 2 H, H-3), 3.66 (m, 2 H, H-4), 3.94 (app d, J = 3.3 Hz, 2
H, H-5), 3.70 (m, 4 H, H-6a + H-6b), 4.58 (d, J = 10.2 Hz, 2 H,
H-1), 3.36 (app t, 2 H, H-2), 3.64 (app t, 2 H, H-3), 3.68 (dd, 2
H, H-4), 3.99 (m, 2 H, H-5), 3.72 (m, 4 H, H-6a + H-6b; Gal
unit: H-1–H-6b; Gluc unit: H-1–H-6b), 1.32 [m, 8 H, C(O)-
NHCH2CH2CH2], 1.52 [m, 8 H, C(O)NHCH2CH2], 3.20 [m, 8 H,
C(O)NHCH2], 2.61 (m, 4 H, SCH2CH2), 2.98–3.01 (m, 4 H,
SCH2), 3.23 [s, 4 H, DTPA amide NCH2C(O)], 3.76 (s, 2 H, DTPA
central acetate NCH2CO2–), 3.38 (s, 4 H, DTPA terminal acetate
NCH2CO2–), 3.37, 3.08 (8 H, two m, DTPA skeleton NCH2) ppm.
13C NMR (75.6 MHz, D2O): δ = 103.08 (C-1), 71.15 (C-2), 78.42
(C-3), 72.71 (C-4), 60.49 (C-5), 75.55 (C-6), 85.59 (C-1), 72.11 (C-
2), 78.82 (C-3), 75.92 (C-4), 68.76 (C-5), 61.22 (C-6) (Gal unit:
C-1–C-6; Gluc unit: C-1–C-6), 25.86, 25.94 [C(O)
NHCH2CH2CH2], 28.33, 28.47 [C(O)NHCH2CH2], 39.26, 39.58
[C(O)NHCH2], 26.45 (SCH2), 36.61 (SCH2CH2), 58.86 [DTPA
amide NCH2C(O)], 54.33 (DTPA central acetate NCH2CO2–),
59.03, 59.11 (DTPA terminal acetate NCH2CO2–), 50.53, 52.88
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(DTPA skeleton NCH2), 170.60, 173.41, 174.24, 178.82 [DTPA ace-
tate NCH2CO2– and amide NCH2C(O), other CH2C(O)NH] ppm.
HRMS (ESI): calcd. for C56H100N7O30S2 [M + H]+ 1414.5950;
found 1414.5971.
DTPAGal4 (2): Fully protected amino-functionalised divalent thi-
ogalactoside 9 (0.464 g, 0.379 mmol) was deprotected as described
for compound 1a. Reaction with DTPA bis(anhydride) (0.064 g,
0.179 mmol), followed by deprotection and purification afforded
glycoconjugate 2 as an off-white solid (0.240 g, 69% yield over two
steps). 1H NMR (300 MHz, D2O, pH = 7.0): δ = 4.46 (d, J =
9.0 Hz, 4 H, H-1), 3.52 (app t, J = 9.0 Hz, 4 H, H-2), 3.64 (dd, J
= 9.0 and 3.3 Hz, 4 H, H-3), 3.68 (m, 4 H, H-4), 3.95 (app d, J =
3.3 Hz, 4 H, H-5), 3.71 (m, 8 H, H-6a + H-6b), 1.28 [m, 8 H, C(O)
NHCH2CH2CH2], 1.49 [m, 8 H, C(O)NHCH2CH2], 3.18 [m, 8 H,
C(O)NHCH2], 3.48 [m, 4 H, NCH2C(O)], 2.75 (m, 8 H, NCH2),
1.83 (m, 8 H, NCH2CH2), 3.20 (m, 8 H, NCH2CH2CH2), 2.59 (m,
8 H, SCH2CH2), 2.97 (m, 8 H, SCH2), 3.20 [s, 4 H, DTPA amide
NCH2C(O)], 3.71 (s, 2 H, DTPA central acetate NCH2CO2–), 3.33
(s, 4 H, DTPA terminal acetate NCH2CO2–), 3.34, 3.18 (two m, 8
H, DTPA skeleton NCH2) ppm.13C NMR (75.6 MHz, D2O): δ =
86.29 (C-1), 69.66 (C-2), 74.09 (C-3), 79.08 (C-4), 68.95 (C-5), 61.41
(C-6), 25.33 [C(O)NHCH2CH2CH2], 28.53 [C(O)NHCH2CH2],
39.32, 39.18 [C(O)NHCH2], 56.57 [NCH2C(O)], 52.51 (NCH2),
25.38 (NCH2CH2), 37.11 (NCH2CH2CH2), 26.70 (SCH2), 36.52
(SCH2CH2), 59.20 [DTPA amide NCH2C(O)], 54.50 (DTPA cen-
tral acetate NCH2CO2–), 59.11 (DTPA terminal acetate
NCH2CO2–), 50.51, 52.89 (DTPA skeleton NCH2), 170.51, 173.40,
174.48, 178.85 [DTPA acetate NCH2CO2– and amide NCH2C(O)
NH, other CH2C(O)NH] ppm. MS (FAB+, NBA): m/z (%) = 1932
(20) [M+], 1055 (100). HRMS (FAB+, NBA): calcd. for
C78H142N13O34S4 [M + H]+ 1932.8665; found 1932.8576.
Preparation of LnIII Glycoconjugates for NMR Studies: The LnIII
glycoconjugates were prepared by adding a slight excess (1.1 equiv.)
of LnCl3 aqueous solution to an aqueous solution of the glycocon-
jugate. The pH of the solution was slowly adjusted to 5 with KOH
(aq.), stirred at 70 °C for 8 h and adjusted to pH = 7 with KOH
(aq.). Any precipitate was filtered off. The solution was concen-
trated and purified by gel filtration with Sephadex G10, eluting
with water. The relevant fractions were pooled and freeze-dried to
afford the LnIII complexes.
Preparation of GdIII-DTPALac2 for NMRD Measurements: Ini-
tially, the DTPALac2 conjugate was left to react with an excess of
Gd(ClO4)3 stock solution and the excess of metal ion was back-
titrated with Na2H2EDTA solution, allowing the calculation of the
exact concentration of glycoconjugate. The GdIII chelate of DTPA-
Lac2 was prepared by adding an appropriate quantity of the glyco-
conjugate to an aqueous solution of gadolinium perchlorate (3–5%
glycoconjugate excess). The solution pH was slowly adjusted to 7
with KOH (aq.). The GdIII glycoconjugate solution was freeze-
dried and diluted with 25 mm phosphate buffer (pH = 7.4). The
absence of free GdIII in the solution was verified by addition of
xylenol orange indicator.[30] The GdIII concentration (4.63 mm) was
verified by ICP measurement.
Supporting Information (see also the footnote on the first page of
this article): Table containing the proton relaxivities of GdIII–
DTPALac2, and equations for the determination of the relaxivity
parameters.
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